Sandoz

Expanded partnership to help “even the odds” of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana In developed countries, the survival rate for childhood cancer is 80%, while in developing countries it can be as low … Read the full press release →

New data just released in the two largest global pharma markets show the substantial and growing level of savings made possible by increased use of generic medicines. HOLZKIRCHEN, 21-Jun-2017 — /EuropaWire/ — Generic medicines accounted for 62% of all medicines prescribed … Read the full press release →

European Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities. Sandoz now has four biosimilars approved in Europe … Read the full press release →

Total investment of EUR 105 million in Prevalje site reinforces commitment to largest Sandoz business, Anti-Infectives, and single largest global product, broad-spectrum antibiotic amoxicillin-clavulanic acid. The investment will bring 150 new jobs, more than doubling the number of employees at … Read the full press release →

Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®* Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis … Read the full press release →